Search
forLearn
5 / 801 resultslearn nicotinamide
learn NMN
learn Ceramide NP
learn ORPL
Research
5 / 1000+ results
research Revised NPRT Classification System Encompasses Additional Patterns of Male and Female Hair Loss
The updated NPRT system now covers different types of hair loss in men and women.
research How I Do It: Ahmad’s NPRT System: A New Classification System for Documenting Male Pattern Baldness
Dr. Muhammad Ahmad created a simpler system to better describe male pattern hair loss.
research Determination of Vitamin B3 Vitamer (Nicotinamide) and Vitamin B6 Vitamers in Human Hair Using LC-MS/MS
The method can measure vitamin B3 levels in human hair accurately.
research Clinical experience on follicular unit extraction megasession for severe androgenetic alopecia
FUE megasession effectively treats severe hair loss with natural-looking results in one operation.
research Evaluation of 50 Donor Scars Undergoing Hair Restoration Using a New Cosmetic Surgery Scar Assessment Scale
The new Cosmetic Surgery Scar Assessment Scale (CSSAS) was found to be simple and effective in evaluating scars from hair restoration surgeries.
Community Join
5 / 1000+ resultscommunity Protac degradation of the androgen receptor in mice shows good efficacy and no systemic drug could be found
The efficacy of degrading the androgen receptor through dermal application in DP cells, a delivery system for topical drugs that involves dissolving microneedles, and rosemary oil as an alternative anti-androgen.
community Kintor Pharma Announces Completion of Subject Enrollment and Dosing in Phase I Clinical Trial of AR-PROTAC(GT20029) in the US_Kintor Pharmaceutical Limited
Kintor Pharma finished enrolling and dosing participants in a Phase I trial for a hair loss treatment called AR-PROTAC (GT20029). The effectiveness of another drug, pyrilutamide (KX-826), for hair loss will be clearer after a Phase 2 trial expected to complete in January 2023.
community Since there is so much hype for cosmeRNA and HMI-115...
Exploring different treatments for hair loss, such as cosmeRNA and HMI-115 which are small interference messenger RNA that inhibits the DHT receptor and an antibody that binds to the prolactin (PRL) receptor respectively; and researching mechanism and environment of hyperresponders.
community Kintor Pharmaceutical Announces AR-PROTAC (GT20029) Approved for Acne and Androgenic Alopecia Clinical Trials in China
The conversation discusses the approval of Kintor Pharmaceutical's AR-PROTAC (GT20029) for clinical trials in China for acne and androgenic alopecia. One user expresses optimism about new treatments being developed and seeks clarification on how the new drug works, specifically if it temporarily degrades the AR protein to reduce DHT sensitivity in hair follicles.
community Pelage have presented only phase 2a. The rest of phase 2 for PP405 will be presented at a later medical meeting
PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.